Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical TrialSerena Di Cosimo, José Baselga, Mark N. Stein et al.|Clinical Cancer Research|2014Cited by 56
Phase III, placebo-controlled trial (SUCCEED) evaluating ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy: Long-term (≥ 24 months) overall survival results.Jean‐Yves Blay, George D. Demetri, Sant P. Chawla et al.|Journal of Clinical Oncology|2012Cited by 11